The ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed further by the Vitaris. The remaining oncology and dermatology business will be demerged into a new entity named Famy Pharma.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7RDIUg
via IFTTT
0 comments:
Post a Comment